# Clinical Use of EVUSHELD as Pre-exposure Prophylaxis in Real-world Setting in Gulf Cooperation Council Countries

> **NCT05315323** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 550 (actual)

## Conditions studied

- COVID-19

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05315323
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-23
- **Primary completion:** 2024-06-27
- **Final completion:** 2024-06-27
- **Target enrollment:** 550 (ACTUAL)
- **Last updated:** 2025-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05315323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05315323, "Clinical Use of EVUSHELD as Pre-exposure Prophylaxis in Real-world Setting in Gulf Cooperation Council Countries". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05315323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*